Praxis Precision Medicines, Inc. priced a new public offering of 2,212,000 shares of its common stock at $260.00 per share, targeting gross proceeds of approximately $575 million before underwriting discounts and commissions. The offering is being conducted under a shelf registration statement on Form S‑3ASR and is expected to close on or about January 8 2026, subject to customary closing conditions. The company has granted the underwriters a 30‑day option to purchase up to 331,800 additional shares at the offering price.
Continue reading for full analysis...
Praxis Precision Medicines announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its lead candidate, ulixacaltamide HCl, for the treatment of essential tremor. The designation, awarded on December 29, 2025, is based on topline data from the company’s Essential3 Phase 3 program, which demonstrated a clinically meaningful reduction in tremor amplitude and improved patient‑reported outcomes compared with placebo.
Continue reading for full analysis...